Ott_a_222974 8765..8768

Department of Radiology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, Sichuan 610041, People’s Republic of China; Department of Interventional Radiology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, Sichuan 610041, People’s Republic of China; PET/CT Center, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083, People’s Republic of China; Nuclear Department, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083, People’s Republic of China; Department of Pathology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, Sichuan 610041, People’s Republic of China; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, Sichuan 610041, People’s Republic of China; Department of Interventional Radiology, Linshui County People’s Hospital, Guang’an, Sichuan 638500, People’s Republic of China Background: Hepatoid adenocarcinoma (HAC) of the lung, a very rare tumor, has been